-
Recent Posts
Recent Comments
Archives
- February 2022
- January 2017
- July 2016
- April 2015
- March 2015
- September 2014
- May 2014
- February 2014
- January 2014
- December 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- October 2012
- December 2011
- November 2011
- October 2011
- September 2011
Categories
Meta
Tag Archives: slow-release implant formulation
Titan Pharmaceuticals, TTNP, Profile, Summary
Titan Pharmaceuticals | TTNP | Profile | Summary Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), … Continue reading
Posted in Daily Penny Stock Picks
Tagged continuous drug delivery technology, medical therapy, Probuphine, slow-release implant formulation, sublingual, transdermal
Comments Off on Titan Pharmaceuticals, TTNP, Profile, Summary